



Contact: David F. Eastman, CEO
Location: Portland, OR
Email: deastman@gamma-therapeutics.com
Tel: 503.222.2313
Website: www.gamma-therapeutics.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
(NIH-CAP)

Company Profile

Industry Sector: Medical Devices

Company Overview: Gamma Therapeutics is an early stage biotechnology company developing a novel class of CVD risk assays, surgical therapy solutions and combat casualty care products employing human biocompatible proteins.

Target Market(s): CVD diagnostic laboratories (Quest, Alere, Berkeley Heart Lab), hospital clinical laboratories, CVD research universities and institutes.

5 Key Search Terms: cardiovascular, diagnostics, fibrinogen, inflammatory biomarkers.

Key Value Drivers

Technology*: GammaCoeur™ is our CVD risk assay that measures gamma-prime (γ') fibrinogen, a newly-emerging CVD risk marker in blood.

Competitive Advantage: γ' fibrinogen has been shown in major CVD studies, including the Framingham Heart Study, to be elevated by CVD. The Founder of Gamma Therapeutics controls the intellectual property for the monoclonal antibody used in this assay, and has a patent pending on the use of the assay for CVD risk assessment, U.S. #61/314,134. γ' fibrinogen is also an inflammatory biomarker like the widely-used CVD risk marker hs-CRP, but shows 5 times less daily variability than hs-CRP. γ' fibrinogen can also be lowered by exercise, giving physicians a treatment option if levels are high.

Plan & Strategy: Seeking strategic partners, venture and angel investment, channel sales relationships.

*Technology funded by the NHLBI and being commercialized under the NIH-CAP

Management

Leadership:

David Eastman, CEO
David Farrell, FAHA, PhD, Founder and CSO
Jon Oberdorf, PhD, Senior Scientist
Candace Clement, Controller

Scientific Advisory Board:

Kent Thornburg, PhD, M. Lowell Edwards Professor of Medicine; Director, OHSU Heart Research Center.
Sanjiv Kaul, MD, Ernest W. Swigert Distinguished Professor of Medicine; CEO, OHSU Knight Cardiovascular Institute.
Steven Kazmierczak, DABCC, PhD, Professor of Pathology; Director, Clinical Chemistry & Toxicology, OHSU Department of Pathology.
Col. Martin Schreiber, MD, Professor of Surgery; Chief, Trauma, Critical Care and Acute Care Surgery, Director of Adult ICUs, OHSU Department of Surgery.
José López, MD, Executive Vice President for Research, Puget Sound Blood Center.

Product Pipeline

